RxDoctor Payments DataLook up a doctor →

Patrick Hall, MD

Interventional Cardiology · Columbia, SCNPI 1205872850

Payments from drug & device makers

$126,221in general payments, 2019–2025

Across 416 payments — averaging $303.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$59K
  • Abbott$50K
  • Abiomed$4K
  • Edwards Lifesciences$3K
  • Ancora Heart, Inc.$3K
  • Medtronic$1K
  • plus $5K from 35 others

What the payments were for

  • Consulting fees$21,28843%
  • Speaking & faculty fees$3,0006%
  • Travel & lodging$8,10816%
  • Food & beverage$17,55735%
  • Entertainment$680%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$126,221 in reported general payments places this provider in the 85th percentile of 117 interventional cardiology providers in South Carolina.

See all interventional cardiology providers in South Carolina

Medicare billing

Part B allowed, 2024
$328,208
Medicare patients
1,685
Services billed
4,013

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban40$28,894
EntrestoSacubitril/Valsartan13$17,005
JardianceEmpagliflozin17$12,533
Bumetanide16$1,067
Rosuvastatin Calcium24$970
ClopidogrelClopidogrel Bisulfate68$721
Atorvastatin Calcium41$627
Metoprolol Succinate40$620
Valsartan25$437
Losartan Potassium27$401
Carvedilol30$346
Potassium Chloride22$294
Isosorbide Mononitrate ErIsosorbide Mononitrate16$283
Warfarin Sodium14$228
Furosemide60$201

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$551$28,89440 claims
NovartisEntresto$524$17,00513 claims
Boehringer IngelheimJardiance$124$12,53317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 117 interventional cardiology providers in South Carolina.

Other interventional cardiology in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →